UNLABELLED: This prospective study finds that ergocalciferol 50,000 IU three times weekly for four weeks effectively and safely corrects vitamin D inadequacy in nursing home residents. INTRODUCTION: Low vitamin D status is common among nursing home residents and contributes to bone loss, falls and fractures. The objective of this study was to evaluate the efficacy and safety of short course, high dose, oral vitamin D(2) (ergocalciferol) treatment. METHODS: This prospective study included 63 nursing home residents. The 25 with low vitamin D status (serum 25(OH)D < or = 25 ng/ml) received oral ergocalciferol 50,000 IU three times weekly for four weeks; the others received no change to their routine care. Serum total 25(OH)D, 25(OH)D(2), 25(OH)D(3), calcium, parathyroid hormone (PTH), bone turnover markers and neuro-cognitive assessments were obtained at baseline and four weeks. RESULTS:Mean total 25(OH)D concentration increased (p < 0.0001) from 17.3 to 63.8 ng/ml in the treated group and remained unchanged in the comparison group. Serum 25(OH)D(3) remained stable in the comparison group, but declined (p < 0.0001) with D(2) treatment from 15.4 to 9.1 ng/ml. Serum PTH trended down in the treatment group (p = 0.06). No treatment-induced improvement in ambulation, cognition or behavior was observed. No hypercalcemia or other adverse effects were observed with ergocalciferol treatment. CONCLUSION: Four weeks of oral vitamin D(2) supplementation effectively and safely normalizes serum 25(OH)D in nursing home residents.
RCT Entities:
UNLABELLED: This prospective study finds that ergocalciferol 50,000 IU three times weekly for four weeks effectively and safely corrects vitamin D inadequacy in nursing home residents. INTRODUCTION: Low vitamin D status is common among nursing home residents and contributes to bone loss, falls and fractures. The objective of this study was to evaluate the efficacy and safety of short course, high dose, oral vitamin D(2) (ergocalciferol) treatment. METHODS: This prospective study included 63 nursing home residents. The 25 with low vitamin D status (serum 25(OH)D < or = 25 ng/ml) received oral ergocalciferol 50,000 IU three times weekly for four weeks; the others received no change to their routine care. Serum total 25(OH)D, 25(OH)D(2), 25(OH)D(3), calcium, parathyroid hormone (PTH), bone turnover markers and neuro-cognitive assessments were obtained at baseline and four weeks. RESULTS: Mean total 25(OH)D concentration increased (p < 0.0001) from 17.3 to 63.8 ng/ml in the treated group and remained unchanged in the comparison group. Serum 25(OH)D(3) remained stable in the comparison group, but declined (p < 0.0001) with D(2) treatment from 15.4 to 9.1 ng/ml. Serum PTH trended down in the treatment group (p = 0.06). No treatment-induced improvement in ambulation, cognition or behavior was observed. No hypercalcemia or other adverse effects were observed with ergocalciferol treatment. CONCLUSION: Four weeks of oral vitamin D(2) supplementation effectively and safely normalizes serum 25(OH)D in nursing home residents.
Authors: Philip T Liu; Steffen Stenger; Huiying Li; Linda Wenzel; Belinda H Tan; Stephan R Krutzik; Maria Teresa Ochoa; Jürgen Schauber; Kent Wu; Christoph Meinken; Diane L Kamen; Manfred Wagner; Robert Bals; Andreas Steinmeyer; Ulrich Zügel; Richard L Gallo; David Eisenberg; Martin Hewison; Bruce W Hollis; John S Adams; Barry R Bloom; Robert L Modlin Journal: Science Date: 2006-02-23 Impact factor: 47.728
Authors: Russel Burge; Bess Dawson-Hughes; Daniel H Solomon; John B Wong; Alison King; Anna Tosteson Journal: J Bone Miner Res Date: 2007-03 Impact factor: 6.741
Authors: J Y Reginster; R Deroisy; H Pirenne; I Frederick; W Dewe; A Albert; J Collette; S X Zheng; C Gosset Journal: Osteoporos Int Date: 1999 Impact factor: 4.507
Authors: A M Grant; A Avenell; M K Campbell; A M McDonald; G S MacLennan; G C McPherson; F H Anderson; C Cooper; R M Francis; C Donaldson; W J Gillespie; C M Robinson; D J Torgerson; W A Wallace Journal: Lancet Date: 2005 May 7-13 Impact factor: 79.321
Authors: Joan M Lappe; Dianne Travers-Gustafson; K Michael Davies; Robert R Recker; Robert P Heaney Journal: Am J Clin Nutr Date: 2007-06 Impact factor: 7.045
Authors: Anand Vaidya; Bei Sun; Carol Larson; John P Forman; Jonathan S Williams Journal: J Clin Endocrinol Metab Date: 2012-04-26 Impact factor: 5.958
Authors: David J Llewellyn; Iain A Lang; Kenneth M Langa; Graciela Muniz-Terrera; Caroline L Phillips; Antonio Cherubini; Luigi Ferrucci; David Melzer Journal: Arch Intern Med Date: 2010-07-12
Authors: N Binkley; D Coursin; D Krueger; P Iglar; J Heiner; R Illgen; M Squire; J Lappe; P Watson; K Hogan Journal: Osteoporos Int Date: 2016-11-08 Impact factor: 4.507
Authors: David B Matchar; Choy-Lye Chei; Zhao-Xue Yin; Victoria Koh; Bibhas Chakraborty; Xiao-Ming Shi; Yi Zeng Journal: J Gerontol A Biol Sci Med Sci Date: 2016-07-12 Impact factor: 6.053
Authors: Y Rolland; P de Souto Barreto; G Abellan Van Kan; C Annweiler; O Beauchet; H Bischoff-Ferrari; G Berrut; H Blain; M Bonnefoy; M Cesari; G Duque; M Ferry; O Guerin; O Hanon; B Lesourd; J Morley; A Raynaud-Simon; G Ruault; J-C Souberbielle; B Vellas Journal: J Nutr Health Aging Date: 2013-04 Impact factor: 4.075
Authors: Amy H Warriner; Ryan C Outman; Kenneth G Saag; Sarah D Berry; Cathleen Colón-Emeric; Kellie L Flood; Kenneth W Lyles; S Bobo Tanner; Nelson B Watts; Jeffrey R Curtis Journal: South Med J Date: 2009-04 Impact factor: 0.954
Authors: Gustavo Duque; Stephen R Lord; Jenson Mak; Kirtan Ganda; Jacqueline J T Close; Peter Ebeling; Alexandra Papaioannou; Charles A Inderjeeth Journal: J Am Med Dir Assoc Date: 2016-06-24 Impact factor: 4.669